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Background: p300/CBP associating factor (PCAF, also known as KAT2B for lysine acetyltransferase 2B) is a catalytic
subunit of megadalton metazoan complex ATAC (Ada-Two-A containing complex) for acetylation of histones.
However, relatively little is known about the regulation of the enzymatic activity of PCAF.
Results: Here we present two dimeric structures of the PCAF acetyltransferase (HAT) domain. These dimerizations
are mediated by either four-helical hydrophobic interactions or a ß-sheet extension. Our chemical cross-linking
experiments in combined with site-directed mutagenesis demonstrated that the PCAF HAT domain mainly forms
a dimer in solution through one of the observed interfaces. The results of maltose binding protein (MBP)-pulldown,
co-immunoprecipitation and multiangle static light scattering experiments further indicated that PCAF dimeric
state is detectable and may possibly exist in vivo.
Conclusions: Taken together, our structural and biochemical studies indicate that PCAF appears to be a dimer
in its functional ATAC complex.
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The unique posttranslational modification patterns on
histones have been conceptualized as epigenetic codes
that may finely tune transcription of specific genes [1,2].
Histone acetyltransferases (HATs), including p300/CBP
and PCAF/GCN5, are responsible for modification of
histones by acetylation on the exposed lysines [3-5].
PCAF/GCN5 are important members of histone ace-
tyltransferases. Homozygous GCN5 knockout mice died
during embryogenesis, while the majority of PCAF knock-
out mice developed normal [6,7]. However, the PCAF
knockout mice later showed memory impairment, psycho-
logical anxiety and defects in stress control [8,9]. Interest-
ingly, a single nucleotide polymorphism in the PCAF gene
was found in patients with coronary heart abnormalities
that resulted in vascular morbidity and mortality [10].
Metazoan PCAF/GCN5 proteins have three conserved
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reproduction in any medium, provided the orbromodomain (BRD) [11]. The HAT and BRD are also
highly conserved in yeast and plants [12,13]. The HAT
domain of PCAF/GCN5 has a globular structure that
contains an acetyl-CoA binding pocket [14,15]. Acetyl-
CoA binds the HAT domain through the pyrophosphate
body and pantetheine arm [16,17]. Substrates of histones
and non-histones, such as p53, induce large conform-
ational changes in the active pocket of the PCAF HAT
domain through extensive interactions that anchor spe-
cific lysines for acetylation [16,18]. Interestingly, PCAF/
GCN5 have slightly different specificity. GCN5 acetylates
histones H3 and H4 with favorable sites of lysines 9 and
14 on histone H3 and lysines 8 and 16 on histone H4
[19]. In comparison, PCAF mainly acetylates lysine 14
on H3 [20] and also specifically acetylates p53 at lysine
320 to enhance responses to DNA damage [21,22].
More importantly, the metazoan PCAF/GCN5 are
usually present in the megadalton complexes SAGA
(Spt-Ada-GCN5-acetyltransferase) and ATAC (Ada-Two-
A containing complex) [11,23]. The additional compo-
nents Ada2 and Ada3 (alteration/deficiency in activation)
are required to form a minimal core complex that can effi-
ciently acetylate histone octamer and nucleosome [24,25].
In addition to a PCAF binding domain, Ada2 has a
SWIRM domain that binds nucleosomal DNA [26]. A. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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direct histone tails to specifically associate with PCAF
catalytic site [27-29]. Through a structurally unknown C
terminal domain Ada3 physically associates with Ada2 in
the core complex [30]. However, the molecular mechan-
ism of this core complex in the regulation of PCAF/
GCN5 catalytic activity and specificity remains largely
unknown.
In this report we present structure-based biochemical
characterization of the PCAF HAT domain. We show
that the PCAF HAT domain can form a dimer in a con-
centration dependent manner. All our experimental data




The PCAF HAT domain (amino acids 493-658) was
purified and crystallized in a unique condition that con-
tained 1.2 M ammonium sulfate and 0.2 M lithium sulfate.
The structure was solved by molecular replacement. To
our surprise, we found four HAT domains in one asym-
metric unit (Additional file 1: Figure 1S). The structure of
each HAT domain remains almost the same globular fold-
ing (root mean square deviation (rmsd) of 0.032-0.035 forFigure 1 Dimeric structures of the PCAF HAT domain. A) The PCAF dim
structure mediated by β-sheet extension; C) Close-up view of detailed inte
view of detailed interactions in the PCAF dimeric interface shown in B. The
cyan, magenta, green and blue. Helices, β-strands and loops are labeled w
sticks (A and B). Amino acids that are involved in direct contacts are repre
indicated with yellow broken lines.Cα backbone). The overall structure is similar to the
PCAF structure (rmsd of 0.397 for Cα backbone) solved
by Marmorstein and his co-workers [17], except for the
loop 1 (L1), which was not defined due to lack of clear
electron density (Additional file 1: Figure S2A and S2B, in-
dicated by arrow). Our PCAF structure is also similar to
human GCN5 (rmsd of 0.34 for Cα backbone) [31] and
Tetrahymena GCN5 (rmsd of 0.902 for Cα backbone)
[16]. In addition to the L1, loop 2 (L2) is also significantly
different from Tetrahymena GCN5, which is bound by a
histone peptide (Additional file 1: Figure S1C and S1D, in-
dicated by arrow).
We found that the four PCAF HAT domains in one
asymmetric unit form two different dimers (Figure 1A and
B). The residues of both interfaces were very well defined
on electron density maps (Additional file 1: Figure 3S).
The first dimer is formed by four-helical stacking of heli-
ces α1 and α2 (Figure 1A and C) and has a canonical
interface with a buried surface area of 1530 Å2. The four
residues Leu512, Val516, Thr535 and Phe539 from both
monomers form a central hydrophobic core, while Gln519
and Asn520 create four pairs of hydrogen bonds. In
addition, Met513 and Thr535 or two His524 residues lo-
cated at the periphery of the interface make additional van
der Waals contacts.er structure mediated by a four helical bundle; B) The PCAF dimer
ractions within the PCAF dimeric interface shown in A; D) Close-up
structures are presented in ribbon with each monomer colored in
ith α, β and L, respectively. The cofactor acetyl-CoA is represented in
sented as sticks and also labeled (C and D). Hydrogen bonds are
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ated through the ß-sheet extension of two antiparallel
ß1 strands (Figure 1B and D). The major contacts of this
dimer are three hydrogen bonds between amino acids
493-495. This interface is further stabilized by a hydro-
gen bond from two His588 residues and van der Waals
contacts from two Ile494 and Tyr585 and His588 from
each monomer. The buried surface area of this interface
is 879 Å2.
Taken together, the results show that the PCAF HAT
domain forms two distinct dimers. The clusters of hydro-
phobic residues contribute their important roles to the in-
teractions. While the first interface is significant, however,
the second interface may likely be produced during crystal
packing due to the smaller size and insignificant score cal-
culated by PISA program (Additional file 1: Table S1).
PCAF dimers detected by pulldown experiments
We next wanted to know whether PCAF HAT domain
exists as a dimer in solution. We first used a maltose
binding protein (MBP) affinity pulldown experiment.
The PCAF HAT domain in MBP fusion was used to pull
down another one in His-tag fusion (Figure 2A). His-
tagged PCAF was clearly observed in beads fraction
when incubated with MBP-PCAF but not in MBP alone
(lanes 5 and 6) compared with a loading control (lane 1).
In order to analyze PCAF oligomeric state in cells, we
performed a co-immunoprecipitation experiment using
HA and Flag tags (Figure 2B). The full-length PCAF was
tagged with either HA or Flag peptides at its N terminus.
Flag affinity gel was used to bind Flag-PCAF. TheFigure 2 PCAF HAT domain interacts with each other in
solution. A) MBP pulldown experiment using an MBP-PCAF HAT
domain fusion. Purified MBP-PCAF fusion proteins were treated
with 2 M NaCl to remove any bound maltose and mixed with
new amylose beads and His-tagged PCAF fragments (lanes 4-6).
The beads were then washed off unbound proteins and analyzed
by 15% SDS-PAGE. Ten percent inputs of His-tagged PCAF fragments,
MBP alone and MBP-PCAF fusion protein were used as loading
controls (lanes 1-3). B) The presence of PCAF dimer state examined
by co-immunoprecipitation. A plasmid that expresses Flag-PCAF was
co-transfected with an empty vector pLV-nHA (lane 1) or HA-PCAF
expression plasmid (lane 2). The expressions of Flag-or HA-PCAF were
confirmed using 5% input shown at the bottom, while the Flag gel
after wash was checked by western blotting as shown at the top.HA-PCAF was readily detected when Flag-PCAF was
co-expressed (lane 2), suggesting that over-expressed
PCAF may self-associate to form oligomers in cells.
PCAF dimers disrupted by mutations in interfaces
To confirm the presence of the PCAF dimers in solution
we then used a chemical cross-linking method (Figure 3).
We observed a dominant dimer on SDS-PAGE after the
PCAF HAT domain was incubated with a cross-linker
disuccinimidyl suberate (DSS) (lane 2, indicated by green
arrow). A ladder of higher molecular-weight oligomers
was also appeared (lane 2, indicated by red arrow).
We continued to examine whether mutations in PCAF
dimerization interfaces would affect its dimers’ forma-
tion. To disrupt the first interface, we generated a tripleFigure 3 PCAF HAT domain dimer detected by chemical
cross-linking. A) Chemical cross-linking of the full-length PCAF
HAT domain (amino acids 493-658). WT represents the full-length
wt PCAF HAT domain (lanes 1-2). LV512DD is a full-length HAT
domain with L512D and V516D double mutations (lanes 3-4).
LMV512AAA is a full-length HAT domain with L512A/M513A/
V516A triple mutations (lanes 5-6). F539A is a full-length HAT domain
with single F539 to alanine mutation (lanes 7-8). B) Cross-linking of a
shortened PCAF HAT domain (amino acids 496-658) in comparison
with a full-length PCAF HAT domain mutant. LVF512DDA is a
combined mutant of LV512DD and F539A in the full-length PCAF
HAT domain (lanes 3-4). LV2DD is a double mutation (L512D and
V516D) in the shortened PCAF HAT domain (lanes 5-6) while
LVF2DDA is a triple mutation (L512D, V516D and F539A) in the
shortened HAT domain (lanes 7-8). The arrows indicate monomer
(black), dimer (green) and higher oligomers (red). Lanes where DSS was
added are indicated above the gel and M denotes a protein molecular
weight marker.
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alanine) (Figure 1C). However, this mutant did not appear
to affect the PCAF dimerization (Figure 3A, lane 6). In
comparison, a mutant with the Leu512 and Val516 altered
to aspartic acid (LV512DD) and Phe539 to alanine
(F539A) did have small effects on the presence of PCAF
dimer and higher oligomers (Figure 3A, lanes 4 and 8). An
LV512DD and F539A combined mutant LVF512DDA was
clearly less prone to form a dimer (Figure 3B, lane 4).
To disrupt the second interface, we removed the first
three N terminal amino acids (amino acids 493-495)
that are responsible for β-sheet extension (Figure 1D).
However, the shortened PCAF HAT domain itself be-
haves as the wt PCAF in this experiment (Data not
shown). The shortened PCAF HAT domain (amino
acids 496-658) was then combined with mutations of
the first interface studied above (Leu512 to Asp,
Val516 to Asp and/or Phe539 to Ala) to generate two
mutants (LV2DD and LVF2DDA). As expected, both
mutations, in particular the LVF2DDA, clearly suppressed
dimer formation of the HAT domain (Figure 3B, lanes 6
and 8).
These data support our crystallographic observation
that both interfaces contribute to the dimeric formation
of PCAF in our cross-linking experiment. However, the
second interface may result from a crystal packing as
suggested by our crystallographic analyses since the de-
letion mutant (amino acids 496-658) did not change its
ability to form a dimer. It is important to note that our
introduction of these mutations into PCAF did not affect
enzymatic activity of PCAF HAT domain (Additional
file 1: Figure S4).
PCAF dimer detected by static light scattering
To seek more evidence for presence of dimers in solu-
tion, we analyzed PCAF HAT domain using Multiangle
static light scattering (MALS), which measures absolute
molecular weight (MW) of a particle without any as-
sumptions. A protein is first separated on a HPLC that
is directly connected with detectors for measuring differ-
ential refractive index (dRI) and light scattering (LS).
The theoretical MW of the HAT domain (amino acids
493-658) including N terminal His tag is 21.8 kDa. Here
three different protein concentrations at 2, 6 and 20 mg/
ml were used in this experiment (Figure 4). The peak 1
was analyzable only at 20 mg/ml, which was determined
to be 49.2 kDa. The major portion of this protein
remained in peak 2, which had the closest MW to
PCAF HAT domain monomer at 2 mg/ml. The MW of
peak 2 was 27.8 kDa at 6 mg/ml and 30.7 kDa at
20 mg/ml, suggesting that part of large particles from
peak 1 was not separable. All these data indicate that
PCAF HAT domain may remain in a dimer-monomer
equilibrium with dominant monomeric species in solution.Discussion
Protein acetylation is well known for its role in epigen-
etic regulation of transcription and is also involved in
translation, protein turnover, localization and quality
control, thus linking acetylation to a variety of biological
processes such as cell shape, migration and autophagy
[32]. Moreover, PCAF/GCN5 family members have been
implicated in carcinogenesis and drug targets for cancer
therapy [33]. Marmorstein and his coworkers have ex-
tensively studied the structures and enzymatic mechan-
ism of the catalytic domain and histone binding of these
histone acetyltransferases [15,34]. Here in this report,
our structural and biochemical analyses demonstrate
that PCAF can exit as a dimer.
We solved the crystal structure of the PCAF HAT do-
main in two different dimeric states. One of these dimeric
interfaces is large (more than 1500 Å2) created by several
hydrogen bonds and hydrophobic contacts (Figure 1). The
second interface is rather small, which may likely be gen-
erated during crystal packing (Additional file 1: Table S1).
The crystals in this study were grown in 0.2 M lithium sul-
fate and 1.2 M ammoniumn sulfate at pH7.5, which were
packed in the space group P43. The same human PCAF
HAT domain was crystallized with space group P64 in a
slightly different condition and no interfaces were found
between its symmetric or asymmetric units [17]. We also
crystallized human GCN5 HAT domain in a simple pre-
cipitant of 35% tacsimate pH 7.0 from Index screen kit
(Hampton Research) and the crystal was packed in a space
group I422 (a = b =129.2 and c = 179 Å) (Data not shown).
Consistently, we found 4 GCN5 monomers in one asym-
metric unit that form the same dimeric interfaces as those
described above for PCAF (Additional file 1: Figure S5A
for the major interface). The GCN5 dimer was well
aligned with the PCAF with rmsd of 1.7 Å (Additional
file 1: Figure S5B).
For comparison, we listed all crystal structures of
PCAF/GCN5 homologues from tetrahymena, yeast and
human (Additional file 1: Table S2). In one crystal form
of a tetrahymena GCN5 HAT domain, a dimeric inter-
face is also formed through anti-parallel helices H1 and
H2 between two HAT domains in one asymmetric unit
(Additional file 1: Figure S6A and S6B). Unfortunately,
based on our PISA analysis, this interface is likely pro-
duced by a crystal packing (Additional file 1: Table S1).
Consistently, two critical residues Met513 and Gln519
that are responsible for dimerization in human PCAF
are replaced with two lysines in tetrahymena GCN5
(Additional file 1: Figure S6C).
In order to confirm whether the human PCAF HAT
domain appears dimers in solution, we performed a
series of experiments, including MBP pulldown, cross-
linking and MALS (Figures 2, 3, 4). All these data sup-
ported that the PCAF HAT domain is able to form a
Figure 4 Molecular weight of PCAF HAT domain determined by MALS. A) A running profile of PCAF protein at concentration of 20 mg/ml.
PCAF HAT domain was first run on a gel filtration column detected by light scattering (LS11, shown in red) and refractive index (dRI, shown in
blue). The X axis is a running time taken from the HPLC. The LS11 (one of 18 light scattering detectors) and dRI intensities are aligned and scaled.
A relative scale is shown as the Y axis. Peak 1 is small and thus highlighted by an arrow. B) The molecular weight of the PCAF HAT domain at
different concentrations. The measurements are colored in green (2 mg/ml), blue (6 mg/ml) and red (20 mg/ml). The dotted lines represent
averaged values for molecular weight calculated by 18 laser detectors at each time point. The X axis is the same HPLC running time as (A) and
the Y axis indicates molecular weight. C) The molecular weights of two PCAF particles in solution. The number in parenthesis is an error rate,
which was calculated using the measurements of all time points for each peak in panel B. ND is ‘Not able to Determine’ because of low signal.
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that the dimer forms only at low ratio because it could
only be readily detected at higher protein concentration
(Figure 4). The apparent MW was close to the theoret-
ical one only at the lowest protein concentration, sug-
gesting the larger MW was likely resulted of presence of
the PCAF dimer.
Interestingly, the N terminal BRD domain of BRD2
protein has been found to be a dimer, allowing to signifi-
cantly enhance the binding to histone H4 and aides with
further recognition of the hypoacetylated H4K8 [35,36].
Indeed, the BRD domains of the PCAF/GCN5 family
members also form dimers in crystallographic conditions
(3D7C and 3GG3, Structural Genomics Consortium),
which have relatively large interfaces (Additional file 1:
Table S1). Even though their significant scores are 0, asynergistic effect of the HAT and BRD domains in dimer
formation may possibly stabilize PCAF oligomeric state
in vivo.
Conclusions
Since PCAF/GCN5 always exist in megadalton com-
plexes, one possibility is that PCAF dimerization may
help to better associate with a nucleosome for efficient
histone acetylation, which is depicted in our proposed
model (Figure 5). PCAF/GCN5 attach to the nucleo-
somal DNA through Ada2 SWIM domain. PCAF/GCN5
bromodomain dimer may further dock the histone H4
through the H4K5 and H4K15 sites, which are acetylated
before incorporated into the nucleosome [37]. The HAT
domain dimer then recruits a histone H3 tail for acetyla-
tions at H3K14 and neighbor sites, including H3K9 and
Figure 5 A hypothetical model of core PCAF/GCN5 complex
interacting with nuleosome for histone acetylation. Shown in
the bottom is a half nucleosome, which is made from the crystal
structure solved by Luger et al [39]. An oligomer of histone H3 and
H4 is wrapped with two double-strand DNA helices. The N terminal
tails of H3 and H4 are extended manually. The three subunits of the
PCAF/GCN5 core complex, including Ada2 and Ada3, are drawn
schematically as a heterohexamer. The arrows indicate experimentally
verified interactions between histone tails, DNA double strands and all
individual domains.
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ate with the H3 and H4 tails and help to better position
these for the acetylation process. Therefore, all these do-
mains contribute to the overall acetylation level and speci-
ficity of histones even though their interactions with
histones and DNA are extremely weak per se. Interestingly,
the 3D reconstruction of complex SAGA has positioned
GCN5 and other BRD-containing proteins in adjacent re-
gion, which may lead to a better association of SAGA and
histone tails through multiple interactions [38].
In summary, our structural and biochemical studies sug-
gest that the PCAF/GCN5 HAT domain can form a dimer
in solution. We propose a model that this dimerization
may be important for acetylations on specific sites of his-
tones since multiple contacts may synergistically position
PCAF/GCN5 megadalton complexes on the nucleosome.
An important question whether PCAF/GCN5 are di-
mers in their functional complexes is currently under
our investigations.Methods
Protein expression and purification
Gene fragment encoding residues 493-658 of human
PCAF HAT domain was amplified by PCR and sub-
cloned into pET28a vector (Novagen) using NheI and
XhoI restriction sites. Site-specific mutations and trunca-
tions were made using the modified Quikchange muta-
genesis protocol [40]. The constructs were then used to
express PCAF in Echerichia. coli stain BL21/DE3 (gold)
using 0.25 mM isopropyl-ß-D-thiogalactopyranoside
(IPTG) for 12 h at 25°C. PCAF proteins were purified by
nickel affinity agarose (Qiagen) and Superdex 200 (GE
Healthcare) according to the manufactures’ protocol.
Purified proteins were concentrated down to ~20 mg/ml
using centricons (Millipore) and stored at −80°C in a
buffer of 20 mM Tris pH8.0, 100 mM NaCl, 300 mM
ammonium acetate, 5 mM ß-mercaptoethanol (ß-ME).
Protein crystallization
Initial crystals of the PCAF HAT domain were obtained
by screening with JCSG plus (Qiagen) in one condition
of 0.2 M lithium sulfate, 0.1 M Tris pH8.5 and 1.25 M
ammonium sulfate. Further optimizations yielded the
crystals in 0.2 M lithium sulfate, 0.1 M HEPES pH7.4,
1.2 M ammonium sulfate and 10 mM trimethylamine
HCl. The crystals were harvested and snap-frozen in li-
quid nitrogen for diffraction data collection after a quick
soaking in a buffer of 0.1 M HEPES pH7.4, 0.2 M lithium
sulfate, 1.6 M ammonium sulfate and 15% isopropanol.
Structural determination
Data were collected in Shanghai Synchrotron Radiation
Facility (SSRF) and processed by HKL2000 [41]. The so-
lution was found by molecular replacement using Phaser
[42]. The model was rebuilt in Coot [43]. The final
structure was refined and the model statistics (Table 1)
were calculated using Phenix [44]. The buried surface
area was calculated by PISA program [45]. All graphics
for the various structures were produced using Pymol
(DeLano Scientific LLC).
Maltose binding protein (MBP) pulldown
MBP-PCAF HAT domain (amino acids 493-658) fusion
protein and MBP alone were expressed in pMBP-c, a
modified vector from pMAL-c2x (NEB) with convenient
restriction and thrombin cleavage sites. The fusion pro-
tein and MBP were purified using amylose agarose (New
England Biolab). An extra C terminus of the MBP alone
(~30 amino acids) using this empty pMBP-c vector was
sensitive to protease cleavage and showed two bands in
our SDS-PAGE. All bound maltose was efficiently re-
moved by running these proteins on a gel filtration
Superdex 200 (GE Healthcare) using a high salt buffer of
30 mM Tris pH8.0, 2 M NaCl, 5 mM ß-ME and 3 mM
Table 1 Data collection and refinement statistics
Space group P 43
Unit cell parameters (Å) a = b = 65.57 Å, c = 187.62 Å
Resolution (Å) 50.0-2.31 (2.35-2.31)†
Reflections (Total/Unique) 344112/32820
††I/σ (I) 45.7 (3.1)
*Rsym (%) 11.8 (55.1)
Completeness (%) 94.9 (62.5)
Refinement
Resolution (Å) 45.26-2.31 (2.37-2.31)
Reflections (after 2σ cutoff) 32806 (2376)
Completeness (after 2σ cutoff) (%) 95.0
‡R (%) 22.8 (28.3)
**Rfree (%) 26.5 (33.7)
Model quality
§RMSD bond length (Å) 0.012
RMSD bond angles (°) 1.261
Overall B-factor (Å2) 80.2
Ramachadran plot 98.9% (favorite)
1.1% (allowed)
0% (disallowed)




†The data for the highest resolution shell are shown in parenthesis.
*Rsym = S|I- < I > |/SI, where I is the observed intensity, <I > is the statistically
weighted average intensity of multiple observations of symmetry-related
reflections. ‡R = S||Fo|–|Fc||/S|Fo|, where Fo and Fc are observed and calculated
structure factor amplitudes, respectively. **Rfree is calculated for a randomly
chosen 10% of reflections. §RMSD–root mean square deviation. ††I/σ(I)–ratio of
mean intensity to a mean standard deviation of intensity. *** Number of protein
atoms and nucleic acid atoms–the ordered region.
Shi et al. BMC Structural Biology 2014, 14:2 Page 7 of 9
http://www.biomedcentral.com/1472-6807/14/2EDTA. The MBP or MBP-PCAF proteins (60 μg) were
then rebound with 10 μl new amylose agarose beads and
60 μg His-tagged PCAF (amino acids 493-658 and 493-
832) in a binding buffer of 50 mM Tris pH8.0, 150 mM
sodium chloride, 5 mM ß-ME and 3 mM EDTA for 2 h
at 4°C. After 3 washes using the binding buffer added
with 0.03% Triton X-100, the agarose beads were col-
lected and the bound proteins were subjected to a regu-
lar 15% SDS-PAGE. The gel was stained with coomassie
blue.
Co-immunoprecipitation
Plasmid pCI-Flag PCAF of Flag-tagged full-length hu-
man PCAF was purchased from Addgene [13]. The con-
struct expressing HA-PCAF was built on pLV-nHA
vector using EcoRI and XbaI sites and confirmed by
DNA sequencing. Cells 293 T were cultured in DMEM
and 10% fetal bovine serum (Gibco) with 100 μg/mlpenicillin and streptomycin. Co-transfection of both
tagged PCAF expression plasmids (8 μg each) was car-
ried out using standard calcium phosphate method. Cells
were harvested after 48 h and lysed in a lysis buffer
(50 mM Tris–HCl pH7.4, 150 mM NaCl, 1 mM PMSF,
10 μg/ml leupeptin, 2 μg/ml pepstatin, 1 mM EDTA and
1% Triton X-100). The lysed supernatants were incu-
bated with 20 μl anti-Flag M2 affinity gel (Sigma) for
4 h. The Flag gel was then harvested and washed using
the same lysis buffer and directly mixed with SDS sam-
ple buffer. The mixture was resolved by 10% SDS-PAGE.
The gel was blotted to nitrocellulose membrane and fur-
ther detected using anti-Flag or anti-HA antibodies
(Sigma).
Cross-linking
Proteins (wt or mutated HAT domains) were exchanged
to a non-amine buffer (50 mM HEPES pH7.5, 50 mM
sodium sulfate) by dialysis. Protein cross-linking was
carried out using 50 mM disuccinimidyl suberate (DSS)
dissolved in pure dimethyl sulfoxide (DMSO). DSS at 5X
molar concentration was directly added to 10 μl of
1 mg/ml PCAF proteins. The reactions were incubated
for 1 h at room temperature and quenched by adding
0.3 M Tris pH7.5 to reach a final concentration of
30 mM. The reactions were then analyzed using regular
12% SDS-PAGE and stained with coomassie blue.
Multiangle laser light scattering (MALS)
The protein prep of the PCAF HAT domain at 2-20 mg/
ml was first resolved on a size exclusion column (WTC-
010S5, 5 μm silica beads, 7.8 × 300 mm) in a buffer of
50 mM phosphate buffer at pH 7.0 and 150 mM NaCl at
35°C. The HPLC was run on a LabAlliance series 1500
isocratic system at a flow rate of 0.5 ml/min. Data were
then collected on a DAWN HELEOS II laser photometer
at an emission of 658 nm (Wyatt, USA). Molecular mass
was calculated using ASTRA V (Wyatt, USA).
Additional file
Additional file 1: Figure S1. Two dimeric PCAF HAT structures in one
asymmetric unit. Figure S2. Structural comparison of PCAF HAT domain
with its homologues. Figure S3. Electron density map of two dimeric
interfaces. Figure S4. The PCAF mutants are enzymatically active as wt
PCAF. Figure S5. Human GCN5 HAT domain crystallized in a dimeric
state. Figure S6. Dimeric structure of tetrahymena GCN5. Table S1. PISA
analyses of the dimeric interfaces of PCAF/GCN5 crystal structures.
Table S2. Crystal structures of PCAF/GCN5 homologues that have
currently been solved.
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